Hannah Lewis, V K Parisa-Fatemeh Asad Zadeh, Luba Soskin, Jared Worful, Georgine Lamvu
{"title":"Trends in Endometriosis Management: A 10-Year US Claims Analysis.","authors":"Hannah Lewis, V K Parisa-Fatemeh Asad Zadeh, Luba Soskin, Jared Worful, Georgine Lamvu","doi":"10.1016/j.jmig.2025.09.519","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objective: </strong>To examine real-world treatment patterns for endometriosis and their alignment with clinical best-practice recommendations.</p><p><strong>Design: </strong>Observational, retrospective study from 2009 to 2022.</p><p><strong>Setting: </strong>Two large US health insurance claims databases, MarketScan® and OPTUM®.</p><p><strong>Patients: </strong>Women aged 16-45 years with continuous enrollment in OPTUM® and MarketScan® and at least 2 diagnoses of endometriosis. Hysterectomy, menopause or active treatment of malignancy were exclusion criteria.</p><p><strong>Interventions: </strong>Pharmacological therapy (including OCPs, POPs, GnRH analogs, opioids), and surgical management (including laparoscopy and hysterectomy).</p><p><strong>Measurements: </strong>Frequencies, means, Time-to-event Kaplan-Meier curves, and Sankey diagrams were used to examine treatment initiation, frequencies and sequences.</p><p><strong>Main results: </strong>A total of 22,317 participants from OPTUM® and 54,630 from MarketScan® were included. Most of these patients (71.0% OPTUM®, 72.1% MarketScan®) received surgery after diagnosis of endometriosis, whereas medications were prescribed in 42.1% (OPTUM®) and 44.9% (MarketScan®). Surgery was performed as a first-line intervention in 37.6% (n=8,395, including 4,481 laparoscopies and 3,914 hysterectomies in OPTUM®) and 41.8% (n=22,858, including 13,175 laparoscopies and 9,683 hysterectomies in MarketScan®). Among first-line surgeries (n=8,395 OPTUM®, n=22,858 MarketScan®), laparoscopies accounted for over half (53.4%, n=4,481 OPTUM®; 57.6%, n=13,175 MarketScan®), while hysterectomies comprised nearly half (46.6%, n=3,914 OPTUM®; 42.4%, n=9,683 MarketScan®). Pharmacotherapy was used first-line in 49.9% (n=11,135) of OPTUM® and 45.5% (n=24,840) of MarketScan®. Opioids were used first-line in 12.5% (n=2,787) OPTUM® and 12.7% (n=6,932) MarketScan®. Pharmacological therapies were started as first-line intervention within 15-23 weeks, and surgeries were performed within 16-18 weeks after diagnosis. Those with gynecologic comorbidities had a shorter diagnosis-to-treatment interval than those with mental health and pain comorbidities.</p><p><strong>Conclusion: </strong>Therapies for endometriosis are generally started within 4-6 months of diagnosis. Surgery is used more frequently than medical management, and in the majority of cases, surgery was first-line intervention. Opioids are still frequently prescribed despite strong guidelines recommending against their use.</p>","PeriodicalId":16397,"journal":{"name":"Journal of minimally invasive gynecology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of minimally invasive gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jmig.2025.09.519","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Study objective: To examine real-world treatment patterns for endometriosis and their alignment with clinical best-practice recommendations.
Design: Observational, retrospective study from 2009 to 2022.
Setting: Two large US health insurance claims databases, MarketScan® and OPTUM®.
Patients: Women aged 16-45 years with continuous enrollment in OPTUM® and MarketScan® and at least 2 diagnoses of endometriosis. Hysterectomy, menopause or active treatment of malignancy were exclusion criteria.
Interventions: Pharmacological therapy (including OCPs, POPs, GnRH analogs, opioids), and surgical management (including laparoscopy and hysterectomy).
Measurements: Frequencies, means, Time-to-event Kaplan-Meier curves, and Sankey diagrams were used to examine treatment initiation, frequencies and sequences.
Main results: A total of 22,317 participants from OPTUM® and 54,630 from MarketScan® were included. Most of these patients (71.0% OPTUM®, 72.1% MarketScan®) received surgery after diagnosis of endometriosis, whereas medications were prescribed in 42.1% (OPTUM®) and 44.9% (MarketScan®). Surgery was performed as a first-line intervention in 37.6% (n=8,395, including 4,481 laparoscopies and 3,914 hysterectomies in OPTUM®) and 41.8% (n=22,858, including 13,175 laparoscopies and 9,683 hysterectomies in MarketScan®). Among first-line surgeries (n=8,395 OPTUM®, n=22,858 MarketScan®), laparoscopies accounted for over half (53.4%, n=4,481 OPTUM®; 57.6%, n=13,175 MarketScan®), while hysterectomies comprised nearly half (46.6%, n=3,914 OPTUM®; 42.4%, n=9,683 MarketScan®). Pharmacotherapy was used first-line in 49.9% (n=11,135) of OPTUM® and 45.5% (n=24,840) of MarketScan®. Opioids were used first-line in 12.5% (n=2,787) OPTUM® and 12.7% (n=6,932) MarketScan®. Pharmacological therapies were started as first-line intervention within 15-23 weeks, and surgeries were performed within 16-18 weeks after diagnosis. Those with gynecologic comorbidities had a shorter diagnosis-to-treatment interval than those with mental health and pain comorbidities.
Conclusion: Therapies for endometriosis are generally started within 4-6 months of diagnosis. Surgery is used more frequently than medical management, and in the majority of cases, surgery was first-line intervention. Opioids are still frequently prescribed despite strong guidelines recommending against their use.
期刊介绍:
The Journal of Minimally Invasive Gynecology, formerly titled The Journal of the American Association of Gynecologic Laparoscopists, is an international clinical forum for the exchange and dissemination of ideas, findings and techniques relevant to gynecologic endoscopy and other minimally invasive procedures. The Journal, which presents research, clinical opinions and case reports from the brightest minds in gynecologic surgery, is an authoritative source informing practicing physicians of the latest, cutting-edge developments occurring in this emerging field.